TAK takeda.com: Indikator likuiditas cepet

Takeda Pharmaceutical combines a global scientific approach with Japanese stability, leveraging steady medical demand and debt reduction. The critical valuation ratio trend on this GURU.Markets chart reflects solvency, where 0.64 serves as the current metric level. The holding's prospects are based on R&D success in gastroenterology, the efficiency of acquisitions, and the patent protection of key drugs.

The quick ratio assesses the ability of Takeda Pharmaceutical (TAK) to settle current liabilities without liquidating inventory, relying solely on cash and accounts receivable. By analyzing the level of highly liquid assets relative to short-term obligations, an investor can discern the real margin of safety for Takeda Pharmaceutical (TAK). Stable demand for unique orphan drugs ensures a constant cash flow, which confirms the issuer's high solvency and minimizes default risk.